Author: Johanna Stiefler JohnsonPublished: 10 June 2021
Prep: Cook: Serves:
In the latest in our ‘Ask the expert’ series, Estonia-based neurologist Dr Pille Taba discusses how people can prepare for palliative care – and why she thinks a multidisciplinary approach to treatment is even more crucial near the end of life
What is palliative care?
Palliative care is defined by the World Health Organization as an approach that improves the quality of life of patients and their families, when they are facing challenges related to life-threatening conditions. Palliative care was first introduced for pain management and focused mainly on people with cancer, but its reach has broadened by now – involving other chronic conditions that deteriorate physical and mental conditions. These include neurodegenerative conditions such as Parkinson’s disease.
Various models for implementing palliative care exist, with adaptations in specific social, economic and cultural settings. As prevalence of neurodegenerative diseases increases in ageing populations, the need for palliative care services will continue to grow.
What challenges can people with Parkinson’s experience later in life?
As Parkinson’s disease is a progressive condition with variable motor and non-motor symptoms, patients may face considerable problems in late stages. Impairment of functions that are difficult to manage may bring limitations in daily activities and increase dependence.
The problems in later stages of Parkinson’s disease include worsening walking disorders, with postural impairment and falls; speech and swallowing disorders; and progressive functional disability in the hands. They can also include non-motor issues, which may have a negative impact on quality of life – including fatigue and sleep problems with restless legs or REM sleep disorder, bladder problems and constipation, drooling and orthostatic episodes, mood and behavioural disorders, hallucinations and cognitive impairment.
How can palliative care help people with Parkinson’s?
Even with optimal medical support, the problems that people face in later stages of Parkinson’s disease might be difficult to treat. They may in turn lead to a decrease in quality of life, increased burden to caregivers, distress for families, higher rates of emergency hospital admissions and extensive social and care services. A new concept is that people with Parkinson’s disease may need variable palliative care applications in different stages of the disease, and suggests the need for early recognition and intervention.
This makes it essential for people with the condition to have reliable information and emotional support from a Parkinson’s disease team. This support may include discussions on expectations for future, planning of advanced care, and arranging of end of life activities which take into account individual cultural background. Individual and proactive support would help to manage the progressive condition based on personal needs.
Dr Pille Taba.
What is your advice for people with Parkinson’s who are preparing for end of life?
It is very important for people with Parkinson’s disease and their families to be informed. They must recognise the personal needs that need to be managed, and consider incorporating palliative care.
For the best care, trustworthy multidisciplinary support can be very helpful – particularly from healthcare professionals who specialise in solving broad-based problems. This might include a movement disorder physician, nurse, physiotherapist, occupational therapist, speech therapist – or, importantly, a psychologist or chaplain to help manage psychosocial and spiritual problems, taking into consideration cultural and social specificities.
How can healthcare professionals support people with Parkinson’s when they are making decisions about end of life?
Access to resources is a specific issue for different countries and communities, as palliative care and end of life management varies through European countries.
Still, there is an ongoing need for awareness about palliative care among healthcare professionals – especially in the ability to explain the condition’s progression, accompanying problems, interventions for relief and end of life activities. Skills for identifying spiritual distress and arranging an end of life should be included in the expertise of Parkinson’s disease practitioners, to help people with the condition with any legal and financial issues, existential challenges, care plans, wishes for treatment, wills and anything else that needs to be considered.
End of life care can be a difficult topic to discuss. Do you have any advice on starting or having conversations on this subject?
I agree, end of life discussions are not easy. We are often not used to thinking about death.
Conversations about end of life must respect patients’ readiness to discuss these delicate topics, step by step. There should be a choice to make, or not to make, decisions. After identifying care needs in a person with Parkinson’s disease and providing suggestions for their management, healthcare professionals can share how the condition may progress – when the patient is ready. This conversation might be about complications of late stages of the condition, and how specific palliative applications can help manage these problems.
Conversations might involve identifying the person’s wishes about medical and non-medical aspects of end of life; preferences for living at home or being cared for in a care home; treatment preferences, including resuscitation; wishes for the last moments of life; and even funeral wishes. There might be a need to appoint a personal representative to the person with Parkinson’s disease.
How can friends and carers of people with Parkinson’s disease better cope with end of life?
Grief is always stressful for friends and family. But preparing for end of life can help them to cope with sorrow and mourning. It helps when the wishes of our beloved family members have been discussed and taken into account, and there has been some relief in their last days and passing.
Attention must be paid to carers’ problems and needs, as well. Supporting a person at the end of life can be complex. Carers are part of the team supporting a person with Parkinson’s disease – but on the other hand, they may need support themselves. That’s why end of life management should involve caregivers, to help improve quality of life and satisfaction of the whole family.
When saying goodbye to a close family member, it is important to feel that everything was done in their favour in the last days and years.
Need to know
Dr Pille Taba is a neurologist with a subspeciality in movement disorders, including Parkinson’s disease, based in Estonia. She is head of the Department of Neurology and Neurosurgery at the University of Tartu, Estonia, and President of the Estonian Society of Neurologists and Neurosurgeons. For many years, she has been involved in academic research, while also teaching students and treating people with Parkinson’s disease. In addition to arranging a Parkinson’s disease clinic with multidisciplinary team management and taking part in EPDA initiatives, she helped to found the Estonian Parkinson’s Association in 1994, which now has several local branches in the country. In September, she will become chair of the European Section of International Parkinson and Movement Disorder Society.
Palliative care and Parkinson’s disease
The aim of palliative care is to improve quality of life for a person with Parkinson’s disease, along with their family members and carers. As a holistic approach to treatment, palliative care aims to address emotional, psychological and spiritual needs while supporting a patient’s control and choice over certain aspects of care. Anyone at any stage of an illness can receive palliative care, but it is particularly important towards the end of life.
“This is a condition you have to learn to live with”
What’s it like living with ‘advanced’ Parkinson’s disease?
5 days ago
A “revolutionary” step in stem cell therapy for Parkinson’s disease?
Scientists in China have developed a method to help improve stem cell research in mice models of Parkinson’s – which could potentially lead to promising new treatments. The researchers, based at the Chinese Academy of Sciences, identified two cell surface markers of dopamine neurons, which are reduced in Parkinson’s. They injected cells with these markers into the brains of the mice and found that this resulted in “higher therapeutic potency” for improving motor symptoms of the condition. As part of their research, the team also worked to control the variability of donor cells, to help improve therapeutic outcomes for Parkinson’s cell therapy. The researchers, whose study was published in ‘The Journal of Clinical Investigation’, described the findings as a “revolutionary step on the road towards more effective and safer stem cell therapies”.
Could frequent nightmares be an early sign of Parkinson’s disease?
A new study has suggested that experiencing recurrent nightmares and bad dreams could be an early symptom of Parkinson’s disease. Researchers from the University of Birmingham, UK, used data from an existing US study that followed 3818 men, aged 67 or older, over a period of 12 years. Participants who reported experiencing bad dreams at least once a week were followed up. During the follow up, 91 people were diagnosed with Parkinson’s. The results suggested that participants who had frequent bad dreams were twice as likely to develop the condition as those who did not. Commenting on the study, lead author Dr Abidemi Otaiku said: “While we need to carry out further research, identifying the significance of bad dreams and nightmares could indicate that individuals who experience changes to their dreams in older age – without any obvious trigger – should seek medical advice.”
More than £2m awarded to research on mitochondria and Parkinson’s disease
Researchers at UK biotech startup NRG Therapeutics are developing potential treatments that may help slow the progression of Parkinson’s by protecting the mitochondria – a part of every human cell that works to power chemical reactions. The company has now received a £2.68m award from government-backed agency Innovate UK to continue its research. Their research built upon previous findings that damage to mitochondria in the substantia nigra – an area of the brain associated with dopamine – may be linked to Parkinson’s. The scientists developed molecules that keep a ‘pore’ in the mitochondria closed, which stops calcium flowing into it, preventing a process that eventually ruptures the powerhouse of the cell and leads to its death. The new funding award follows previous investment from Parkinson’s UK and the Michael J Fox Foundation.